BCI-137
Based on 1 publication(s) in Google Scholar
BCI-137 is a Argonaute 2 (AGO2) inhibitor. By inhibiting AGO2 function, reducing PTPN6/SHP-1 protein levels and enhancing STAT1 phosphorylation, BCI-137 restores the sensitivity of tumor cells to IFN-γ. BCI-137 effectively enhances the recruitment, activation and cytotoxicity of CD8+ T cells. BCI-137 exerts a synergistic effect with anti-PD-1 antibodies and significantly reduces tumor volume in preclinical mouse models. BCI-137 exhibits favorable safety profiles and does not cause significant weight loss or death in mice. BCI-137 can be used in research related to bladder cancer, colorectal cancer, melanoma and other related fields.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.84%
- No. CAS: 112170-24-8
- Fòrmula: C11H11N3O6S
- Peso molecular:313.29
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
JAK/STAT Compound Library
HY-L008
-
Kinase Inhibitor Library
HY-L009
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
MCE Kinase Hinge Binder Fragment Library
HY-L907
Publications Citing Use of MedChemExpress (MCE) BCI-137
More
Actividad biológica
|
STAT1 |
BCI-137 (5-10 μM) concentration-dependently enhances STAT1 activation induced by 20 ng/mL IFN-γ in both human bladder cancer cell line UMUC-3 and SYBC1, and reduces the expression of PTPN6[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human bladder cancer cell line UMUC-3 and SYBC1
-
Concentration:5 μM, 10 μM
-
Incubation Time:24 h; stimulated with 20 ng/mL IFN-γ
-
Result:Dose dependently enhances STAT1 activation induced by 20 ng/mL IFN-γ in human bladder cancer cell line UMUC-3, and reduces the expression of PTPN6
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice with Bladder cancer (6-8-week-old female, subcutaneous MB49 bladder cancer cell-induced model)[1]
-
Dosage:100 mg/kg
-
Administration:Intermittently; 4 doses every 3 days beginning on day 7
-
Result:Significantly reduced subcutaneous MB49 tumor volume at day 19 when combined with anti-PD-1 antibody.
Increased the percentage of CD8+ T cells infiltrating tumors when combined with anti-PD-1 antibody.
Elevated the percentage of IFN-γ+/CD8+ T cells in tumors when combined with anti-PD-1 antibody.
Elevated the percentage of TNF-α+/CD8+ T cells in tumors when combined with anti-PD-1 antibody.
Prolonged overall mouse survival.
Chemical Information
-
No. CAS 112170-24-8
-
Appearance Solid
-
Peso molecular 313.29
-
Fòrmula C11H11N3O6S
-
Color White to off-white
-
SMILES
CC(C(O)=O)NS(=O)(C1=CC2=C(C=C1)NC(C(N2)=O)=O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
PLoS Biol
Argonaute 2 drives resistance to immune checkpoint inhibitors in immunorefractory non-small cell lung cancer. [Abstract]2026 Jun 18;24(6):e3003860. PMID: 42313870
Solvente y solubilidad
DMSO : 100 mg/mL (319.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.98 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.98 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1919 mL | 15.9597 mL | 31.9193 mL | 79.7983 mL |
| 5 mM | 0.6384 mL | 3.1919 mL | 6.3839 mL | 15.9597 mL | |
| 10 mM | 0.3192 mL | 1.5960 mL | 3.1919 mL | 7.9798 mL | |
| 15 mM | 0.2128 mL | 1.0640 mL | 2.1280 mL | 5.3199 mL | |
| 20 mM | 0.1596 mL | 0.7980 mL | 1.5960 mL | 3.9899 mL | |
| 25 mM | 0.1277 mL | 0.6384 mL | 1.2768 mL | 3.1919 mL | |
| 30 mM | 0.1064 mL | 0.5320 mL | 1.0640 mL | 2.6599 mL | |
| 40 mM | 0.0798 mL | 0.3990 mL | 0.7980 mL | 1.9950 mL | |
| 50 mM | 0.0638 mL | 0.3192 mL | 0.6384 mL | 1.5960 mL | |
| 60 mM | 0.0532 mL | 0.2660 mL | 0.5320 mL | 1.3300 mL | |
| 80 mM | 0.0399 mL | 0.1995 mL | 0.3990 mL | 0.9975 mL | |
| 100 mM | 0.0319 mL | 0.1596 mL | 0.3192 mL | 0.7980 mL |
BCI-137 Related Classifications
HY-119024 Related Classifications
Powered by Bioz